Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics Strengthens Legal Safeguards for Leadership
HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
H.C. Wainwright analyst Robert Burns maintains $Fate Therapeutics(FATE.US)$ with a hold rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 28.6%